Maxcyte Inc (MXCT) — 13F Holders Deep Dive (Q2 2026)

MXCT ranks #4122 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

124 institutions disclose a position in MXCT, but none treat it as a major bet — even Vitruvian Partners LLP, its most concentrated holder, allocates just 3.1% of its own portfolio to it.

MXCT reported a net loss of $35.6M over the trailing twelve months.

• Not yet profitable — net loss of $35.6M over the trailing twelve months
• Revenue declined 19.0% year over year
• Net income improved year over year, from -$44.8M to -$35.6M
• Operating cash flow was negative, using $34.4M in cash
• Current ratio of 8.30x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.18x equity — within a conventional range